Ignite Creation Date:
2024-07-17 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06466122
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-06-07
Brief Title:
Pirtobrutinib LOXO-305 and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Sponsor:
Kerry Rogers
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-22172
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Kerry Rogers
Lead Sponsor Class:
OTHER
Responsible Party:
Kerry Rogers
Responsible Party Title:
Principal Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None